Atara Biotherapeutics Inc (NASDAQ:ATRA) insider Joe Newell sold 1,500 shares of the firm’s stock in a transaction on Monday, May 6th. The stock was sold at an average price of $35.00, for a total value of $52,500.00. Following the completion of the sale, the insider now directly owns 62,998 shares of the company’s stock, valued at approximately $2,204,930. The transaction was disclosed in a document filed with the SEC, which is available through this link.
Joe Newell also recently made the following trade(s):
- On Monday, April 1st, Joe Newell sold 1,500 shares of Atara Biotherapeutics stock. The stock was sold at an average price of $39.96, for a total value of $59,940.00.
- On Friday, March 1st, Joe Newell sold 1,500 shares of Atara Biotherapeutics stock. The stock was sold at an average price of $36.13, for a total value of $54,195.00.
ATRA stock traded down $0.57 during midday trading on Friday, reaching $22.21. The stock had a trading volume of 273,267 shares, compared to its average volume of 556,823. The firm has a market capitalization of $1.08 billion, a price-to-earnings ratio of -4.21 and a beta of 2.11. The company has a debt-to-equity ratio of 0.05, a current ratio of 9.96 and a quick ratio of 9.96. Atara Biotherapeutics Inc has a 52-week low of $21.61 and a 52-week high of $51.40.
ATRA has been the subject of a number of recent analyst reports. ValuEngine cut Atara Biotherapeutics from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, April 10th. Mizuho restated a “buy” rating and issued a $62.00 target price on shares of Atara Biotherapeutics in a research note on Tuesday, February 26th. Cowen restated a “buy” rating on shares of Atara Biotherapeutics in a research note on Tuesday, February 26th. BidaskClub upgraded Atara Biotherapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, February 7th. Finally, William Blair restated an “outperform” rating on shares of Atara Biotherapeutics in a research note on Monday, April 1st. Two analysts have rated the stock with a sell rating, two have given a hold rating and seven have assigned a buy rating to the stock. Atara Biotherapeutics currently has a consensus rating of “Hold” and a consensus target price of $40.20.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in ATRA. Manchester Capital Management LLC purchased a new position in shares of Atara Biotherapeutics during the 1st quarter valued at about $56,000. Quantamental Technologies LLC purchased a new position in shares of Atara Biotherapeutics during the 4th quarter valued at about $62,000. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. raised its stake in shares of Atara Biotherapeutics by 31.7% during the 4th quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 4,042 shares of the biotechnology company’s stock valued at $115,000 after buying an additional 974 shares during the last quarter. Meeder Asset Management Inc. purchased a new position in shares of Atara Biotherapeutics during the 4th quarter valued at about $128,000. Finally, Coastal Investment Advisors Inc. purchased a new position in shares of Atara Biotherapeutics during the 1st quarter valued at about $142,000.
TRADEMARK VIOLATION WARNING: This news story was published by Rockland Register and is owned by of Rockland Register. If you are viewing this news story on another website, it was illegally stolen and republished in violation of US & international copyright laws. The legal version of this news story can be accessed at https://rocklandregister.com/2019/05/31/joe-newell-sells-1500-shares-of-atara-biotherapeutics-inc-atra-stock.html.
Atara Biotherapeutics Company Profile
Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma.
Featured Story: Trading on Margin
Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.